Shots:

• F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star
• Merck KGaA will be responsible for the development and commercialization of the preclinical program and exercised its first license option in May 2019 that brought the first program from the collaboration into its pipeline
• The companies have agreed to the licensing terms for the inclusion of two additional preclinical programs under the existing partnership

Ref: Businesswire | Image: Merck KGaA